Working… Menu
Trial record 85 of 382 for:    IFNA2 AND RBV AND genotype

Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00274495
Recruitment Status : Terminated
First Posted : January 11, 2006
Last Update Posted : November 1, 2007
Information provided by:
Beth Israel Medical Center

Brief Summary:
To study the effectiveness and safety of adding Rosiglitazone, an insulin sensitizing agent to people with chronic hepatitis C infection genotype 1 with fatty liver disease, who are being treated with standard therapy. Standard therapy consists of weekly pegylated interferon injections and daily ribavirin pills, whose dosage is weight based. This regimen in genotype 1 patients is effective in only 45% of patients at best. In addition, this therapy must be given for 48 weeks to be effective and has alot of side-effects. One risk factor for a poor response is fatty liver. Rosiglitazone has been shown to be effective in the treatment of patients with fatty liver alone. This study hopes to show that the addition of Rosiglitazone to the standard therapy in genotype 1 patients with fatty liver disease will increase effectiveness of the standard therapy of hepatitis C.

Condition or disease Intervention/treatment Phase
Chronic Hepatitis C Infection Fatty Liver Drug: Rosiglitazone and Pegasys/Ribavirin Phase 4

Detailed Description:

Eligible thirty subjects will be randomized in a double blinded fashion to either Rosiglitazone 4mg pills twice a day versus placebo for six weeks. Then after this six week period, both groups will be treated for 48 weeks of standard therapy for hepatitis C consisting of Pegasys 180mcq weekly injections with Ribavirin 1,000mg-1,200mg daily depending if the subject weights less than 75 kg will then receive the lower dosage. In addition, the subjects will be continued on Rosiglitazone or placebo for the 48 weeks.

The subjects will be monitored for side-effects by history taking and blood testing at predetermined time periods during the study. If the viral load has not dropped more than two log at week 12 of standard therapy for hepatitis C then therapy will be stopped and the subject is considered a treatment failure. Similarly, if there was a greater than two log drop in the viral load at week 12 but there is still virus present in the blood at week 24 then therapy is stopped and the subject is considered treatment failure. If the virus is undetectable in the blood at week 12 and 24 then therapy is continued for the full 48 weeks. If the virus is detectable at week 48 then the subject is considered a treatment failure.

After this 48 week treatment period and the virus is still undetectable, there is a follow-up period consisting of 24 weeks off therapy. At the end of the 24 weeks, blood will be tested for the virus and if the virus is not present then the subject has a sustained viral response and is a treatment success.

During therapy if the subject becomes significantly anemic Procrit 40,000Units weekly injections will be started. Similarly, if the white blood cell count drops below a certain level then weekly Neupogen 300mcq injections will be started. In addition, if there is mild depressive symptoms treatment will be started but if there is major depressive symptoms, then therapy will be stopped and a referral to a psychiatrist will be made.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Randomized Placebo-Control Pilot Study Evaluating the Efficacy and Safety of Rosiglitazone Combined With Pegylated Interferon Plus Ribavirin Versus Pegylated Interferon Plus Ribavirin Alone in Genotype 1 Hepatitis C With Steatosis
Study Start Date : January 2006
Actual Study Completion Date : October 2007

Primary Outcome Measures :
  1. To compare the efficacy of Rosiglitazone in combination with pegylated interferon alfa-2a and ribavirin (weight-based) to that of pegylated interferon alfa-2a and ribavirin alone in terms of sustained viral response.

Secondary Outcome Measures :
  1. To compare the safety and tolerability of Rosiglitazone in combination with pegylated interferon-2a and ribavirin to that of pegylated interferon alfa-2a and ribavirin alone in terms of adverse events.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women at least 21 years of age.
  • Positive serum hepatitis C RNA for at least 6 months.
  • Naive to any therapy for hepatitis C infection.
  • Significant steatosis or fat on the liver biopsy.
  • Genotype 1 patients.

Exclusion Criteria:

  • Subjects with decompensated liver disease.
  • Hemoglobin <12g/dl.
  • WBC<2,000mm3.
  • ANC<1,000mm3.
  • Platelet count<50,000/mm3.
  • Creatinine>1.5mg/dl.
  • Albumin<2.5g/dl.
  • Bilirubin>4mg/dl.
  • HIV or hepatitis B co-infection.
  • History of other liver disease besides fatty liver disease.
  • History of unstable cardiac or cerebrovascular disease.
  • History of significant psychiatric disorders.
  • Alcohol or drug abuse within last year.
  • Pregnant or lactating women or men whose sexual partner is pregnant or lactating.
  • Taking of insulin or oral hypoglycemic agents within six months of the study.
  • Uncontrolled thyroid disorder.
  • History of malignancy within the past 5 years unless cured by surgery.
  • History of autoimmune disorder or organ transplantations requiring immunosuppression.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00274495

Layout table for location information
United States, New York
Beth Israel Medical Center - Philipps Ambulatory Care Center
New York, New York, United States, 10003
Sponsors and Collaborators
Beth Israel Medical Center
Layout table for investigator information
Principal Investigator: Douglas Meyer, M.D. Beth Israel Medical Center
Study Director: Henry C. Bodenheimer, M.D. Beth Israel Medical Center

Layout table for additonal information Identifier: NCT00274495     History of Changes
Other Study ID Numbers: 098-04
First Posted: January 11, 2006    Key Record Dates
Last Update Posted: November 1, 2007
Last Verified: January 2006
Keywords provided by Beth Israel Medical Center:
Genotype 1
Metabolic syndrome
Insulin resistance
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Fatty Liver
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Hepatitis, Chronic
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Hypoglycemic Agents
Physiological Effects of Drugs